A Comparison of Quantitative Approaches Applied to LC AMS Assay Validation: An Update

July 25, 2012

Accelerator mass spectrometry (AMS), in conjunction with LC, has been applied as a quantitative tool which enables innovative study designs employing 14C enriched analytes. The use of the 14C-label permits the determination of absolute bioavailability, clearance and volume of distribution by IV administration of the 14C analyte concomitant with extravascular pharmacological dose of unlabelled compound. Read More »


Absolute Oral Bioavailability and Metabolic Turnover of Beta-Sitosterol in Healthy Subjects

July 13, 2012

Unilever R&D, Vlaardingen, The Netherlands (G.D.); Unilever Safety & Environmental Assurance Centre, Colworth, United Kingdom (B.C., S.W.); Xceleron Ltd., York, United Kingdom (J.H., D.S., G.L.); and Medical University of Vienna, Vienna, Austria (A.B., M.M., M.Z.)

The metabolic turnover, absolute oral bioavailability, clearance, and volume of distribution for Beta-sitosterol were measured in healthy subjects. [14C]Beta-Sitosterol was used as an isotopic tracer to distinguish pulse doses from dietary sources and was administered by both oral and intravenous routes. Read More »


Xceleron and Lundbeck Publish on the Use of AMS to Meet the MIST Guidelines

March 9, 2012

The metabolites in safety testing and ICH-M3 guidance documents emphasize the importance of metabolites when considering safety aspects for new drugs. Both guidances state that relevant metabolites should have safety coverage in humans (although the guidelines have different definitions of relevant metabolites). Read More »


Single and Multiple-Dose IV and Oral Pharmacokinetics of the Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) During a Phase 1 Study in Healthy Female Subjects

January 31, 2012


This poster, published at the ASCPT meeting in Dallas, Texas, in 2011, describes how scientists at Genentech used the AMS enabled IV tracer approach to investigate the previously observed non-linear pharmacokinetics (PK) of vismodegib (GDC-0449).

By administering a 14C-labelled IV microtracer of Vismodigib in addition to an oral dose, they were able to determine how PK behavior changed with multiple daily dosing relative to a single dose.


Accelerator MS: It’s Role as a Frontline Bioanalytical Technique

December 23, 2011


A paper on a presentation by Dr Mark Seymour on the use of AMS as a frontline technique in bioanalytical detection has been published in the December 2011 issue of Bioanalysis. Read More »


Xceleron Publish Data on Quantitative Target Binding in vivo

November 28, 2011


Target Mediated Disposition of 14C-anti-CEA using Accelerator Mass SpectrometryIt has been shown in a previous study using Iodine-125, that the plasma clearance of T84.66 (anticarcinoembryonic antigen, CEA) in a xenograft mouse model can be used to test for the presence of CEA-positive tumors. Transferring the technique into humans would be problematic because of the low doses of antibody required and the potential radioactive burden required to achieve sufficient assay sensitivity. Read More »


AAPS Poster with AstraZeneca Comparing IV Tracer Design with Oral/IV Crossover Clinical Design

November 24, 2011


A Resource and Data Quality Comparison: Absolute Bioavailability Data from an Oral / IV Crossover and an IV Isotropic Tracer Clinical Design. This poster, presented by AstraZeneca and Xceleron at the meeting of the American Association of Pharmaceutical Scientists (AAPS) in Washington DC in October 2011, describes the us of an IV microtracer study design to obtain information on absolute bioavailability and IV pharmacokinetics. Read More »


AAPS Poster with Unilever and the University of Vienna on Measurement of Metabolic Turnover.

November 9, 2011


Probing Intrinsic Pathways: a Novel Approach to the Measurement of Metabolic Turnover. Studying compounds with high natural occurrence or dietary background in humans is problematic because the dose of metabolite or precursor must be very small to avoid perturbing naturally-occurring pools, intravenous administration is required to obtain clearance and metabolic-turn-over data, and extreme sensitivity is required.  Read More »


Pfizer Scientists Publish Paper on the Utility of AMS Microdosing

October 17, 2011

In this month’s Xenobiotica, scientists from Pfizer, in collaboration with Xceleron, describe a study in which AMS enabled microdosing was used to compare the oral and IV pharmacokinetics of preclinical development drug candidate, PF-4776548.This provided a relatively low cost, clear decision making approach,resulting in the decision to halt further development of PF-4776548, saving money and resources.

Click here to go to the Informa website to see the full abstract.


A Single Dose Mass Balance Study of the Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Humans Using Accelerator Mass Spectrometry

August 14, 2011


Vismodegib (GDC-0449), a small molecule Hedgehog Pathway Inhibitor, was well tolerated in patients with solid tumors and showed promising efficacy in advanced basal cell carcinoma in a Phase I trial. The purpose of the present study was to determine routes of elimination and extent of vismodegib metabolism, including assessment and identification of metabolites in plasma, urine and feces.


  • Latest News

    Pharmaron Acquires Majority Stake in SNBL CPC

    Read more »

  • What our clients are saying about us...

    "...AMS [is] an invaluable tool in our early drug development program, allowing us to quickly assess bioavailability in humans and focus resources on our most promising drug candidates going forward."

    See more client quotes »

  • Get Phase II Ready

    Find out how we can help you accelerate your drug-development program.

    Email us now »

© Xceleron 2018 All Rights Reserved.